Plasma viral load and genotypic resistance patterns in children adding lamivudine to current reverse transcriptase inhibitor therapy (PENTA 4 Trial)

This website uses technical cookies functional to the site's operation, anonymous statistical and, subject to your consent, third party analytical and profiling cookies. In particular, we use cookies and other identifiers to ensure you get the best experience on our website, to provide you with social media features and to analyze our traffic. We also use third party tracking and profiling cookies and identifiers to collect information about how you use the Site and to send you promotional messages in line with your online preferences. By clicking on the Accept all cookies button, you give your consent to the use of all the cookies used in our website. By clicking on the “Cookie settings” button, you can customize your choices regarding cookies used in our website. If you close this banner by clicking the "X" button, default settings will stay as they are and you will continue to browse the Website in the absence of cookies other than technical ones.
You can freely give, refuse or revoke your consent, at any time, by accessing the Management consent panel.
If you would like to learn more about how cookies work on the site, read our Privacy Policy and Cookies Policy.